BIOJECT





California Office:

26212 Dimension Drive, Ste 260
Lake Forest, CA 92630
949-273-8643

Oregon Office:

7180 SW Sandburg Street, Ste 100
Tigard, Oregon 97223
503-692-8001

Customer Service:

800-683-7221 ext 4122

Bios

Company Officers

 
MARK LOGOMASINI has been a Director since December 2009. In February 2015 he became the Director of Business Development, transitioning from President and CEO, a position he held since late 2011.  Mr. Logomasini has experience in life sciences business management and development, drug development, and Federal sector contracting. Prior to joining Bioject, Mr. Logomasini was a partner in Foothill Scientific Associates, a company that provides consulting and resource management services for Federal programs in the life sciences. From 2008 to 2010 Mr. Logomasini was Director of Business Development for the Government Sector Group of SAFC/Sigma-Aldrich Corporation. Mark Logomasini was a Founder and the Chief Financial Officer/VP Business Development for Molecular Medicine BioServices, Inc., a contract biologics development and GMP manufacturing organization acquired by Sigma-Aldrich in 2007. He holds a B.Sc. in Chemical Engineering from the Missouri School of Mines and an M.B.A. (with Honors) from the Merage School of Management at the University of California-Irvine. Mark Logomasini is a certified Project Management Professional (PMP) with the Project Management Institute.

RICHARD R. STOUT, M.D. joined Bioject in April 1994 as Director of Clinical and Regulatory Affairs. He was promoted to Vice President of Clinical Affairs in December 1994 and to Executive Vice President and Chief Medical Officer in March 2007. In March 2007, Dr. Stout became a member of the Executive Committee. From 1992 to 1993 he was the Director of Clinical and Regulatory Affairs at EndoVascular Instruments, Inc., a developer of surgical devices and methods for endarterectomy and intraluminal graft placement. Dr. Stout acted as the Manager of Tachycardia Clinical Studies at Telectronics Pacing Systems, an international medical device company involved in manufacturing and distributing cardiac pacemakers and implantable defibrillators, from 1990 to 1992. From 1987 to 1989, Dr. Stout was Director of Medical Programs at Biotronik Inc., also a manufacturer and distributor of implantable cardiac pacemakers. Dr. Stout holds several technology patents in the DNA and needle-free area. 

TONY K. CHOW was appointed as President and CEO of Bioject in February 2015 and he is also a director of the company. Mr. Chow joined Bioject in July 2014 as Chief Financial Officer. Prior to joining the Company, Mr. Chow was a consultant in financial and operational management roles for domestic and international companies. Mr. Chow consulted in the areas of SEC reporting, financial/IT/J-SOX compliance reporting, and internal/external audits on a project or interim basis. Most recently, Mr. Chow was the Chief Financial Officer at American Laser Healthcare Corporation, a development stage medical device company with SEC reporting. Mr. Chow brings professional services experience with over 30 years in financial management consulting, financial operations including SEC reporting, financial/IT/J SOX compliance, business development, client relationship management, and software product development/implementations. From 1997 to 1999, Mr. Chow was the Director of Asia Sales and Marketing at Digital Video Systems, Inc. From 1994 to 1997, Mr. Chow was the Chief Financial Officer and Corporate Controller at Craig Consumer Electronics, Inc. From 1989 to 1993, Mr. Chow was the Controller of InterTherapy, Inc., a start-up company in the manufacturing and marketing on intravascular ultrasound imaging system and catheter. Mr. Chow holds an MBA degree in Finance, Accounting and Operations Research from the University of California at Riverside. He also earned a BA degree in Economics from the University of the Pacific at Stockton, and a BA degree in Physiology from the University of California at Berkeley. 

Board of Directors

JERALD S. COBBS (Chairman)  has served as a director since March 2006 and was elected Chairman of the Board in March 2013 and served as Chairman from October 2006 until February 2008. Mr. Cobbs brings extensive experience in the health sciences and biotechnology sector to the Board. From March 2007 to September 2008, Mr. Cobbs was appointed as our Interim President and Chief Executive Officer. Mr. Cobbs is the former Chief Commercialization Officer of the Cancer Prevention Research Institute of Texas (CPRIT). Mr. Cobbs was a Managing Director of LOF Partners, LLC, an investment management fund, from 2001 until March 2009. Mr. Cobbs has more than twenty five years experience in the health sciences and biotechnology industries. He was formally head of Healthcare Investment Banking at Harris Webb and Garrison a Houston, Texas merchant banker. Mr. Cobbs previously served as the Assistant Director of Technology Development at the University of Texas - M.D Anderson Cancer Center, in the Houston Medical Center. During his tenure at M.D Anderson Cancer Center, he helped form two molecular therapy companies. Mr. Cobbs was also Chairman and Chief Executive Officer of Quantitative Diagnostic Laboratories, a cancer diagnostic and image analysis company based in Chicago, IL (sold to Ventana Medical Systems now part of Roche). Mr. Cobbs received his M.B.A from the University of Houston. 


DAVID S. TIERNEY, M.D. has served as a director since June 2007 and as Chairman from February 2008 to January 2010. Dr. Tierney’s experience in research and development in drug delivery and specialty pharma companies provides the Board with the depth of knowledge of clinical and regulatory activities. Dr. Tierney is a Biomedical Entrepreneur and was President and Chief Operating Officer for Oceana Therapeutics Inc., a specialty pharmaceutical company. From August 2000 to April 2007, Dr. Tierney served as the President, Chief Executive Officer and Director of Valera Pharmaceuticals, Inc., a specialty pharmaceutical company, until it was acquired by Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV). From January 2000 to August 2000, Dr. Tierney served as President of Biovail Technologies, a division of Biovail Corporation, a Canadian drug delivery company, where he was responsible for all of Biovail’s research and development, regulatory and clinical activities. From March 1997 to January 2000, Dr. Tierney was Senior Vice President of Drug Development at Roberts Pharmaceutical Corporation, where he was responsible for all research and development activities, and for drug development, medical affairs, worldwide regulatory affairs and chemical process development, as well as being part of the executive management team. From December 1989 to March 1997, Dr. Tierney was employed by Élan Corporation, a pharmaceutical company, in a variety of management positions. Dr. Tierney received his medical degree from the Royal College of Surgeons in Dublin, Ireland and was subsequently trained in internal medicine. Dr. Tierney is a director of Catalyst Pharmaceutical Partners (NASDAQ: CPRX).   


 

 

EDWARD L. FLYNN has served as a director since November 2007. Mr. Flynn also served as a member of our Board from 1999 to 2004. Mr. Flynn brings to our Board the extensive experience as a business owner as well as his expertise in the financial and securities fields. Since 1972, Mr. Flynn has been owner and Chief Executive Officer of Flynn Meyer Company, a restaurant industry management company. From 1958 to 1972, Mr. Flynn was a securities broker with Merrill Lynch Pierce Fenner and Smith. He serves as a member of the board of directors and the Chief Financial Officer of Citri-Lite Co. Inc., a soft drink company. He also serves as a member of the board of directors of TGCI Industries (NASDAQ: TGE), a geophysical service company primarily conducting three-dimensional seismic surveys for companies engaged in oil and gas exploration. He is a director of Supreme Industries, a manufacturer of specialized vehicles and truck bodies, and Chase Packaging, a food packaging company. He also serves on the board of trustees of Fordham Preparatory School in New York City. 

 

 

About Us | Products | Focus AreasContact Bioject | Resources & News

 Copyright © 2012 Bioject. All rights reserved.